Your session is about to expire
← Back to Search
Escalation Cohort for Non-Small Cell Lung Cancer
Study Summary
This trial tests a new combination of drugs to treat advanced/metastatic lung cancer. It'll measure safety and effectiveness.
- Non-Small Cell Lung Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the Escalation Cohort achieved regulatory acceptance from the FDA?
"Due to the limited amount of evidence available, Escalation Cohort was ranked a 1 in terms of safety. This is because it is currently undergoing Phase 1 trials which means efficacy and safety have yet to be established."
Is this trial presently admitting participants?
"Affirmative, according to the clinicaltrials.gov records this experimental research is currently recruiting patients. The project was initially made available on February 1st 2023 and has been recently updated on January 11th 2023. This investigation requires 50 participants from two unique locations."
To what extent is this clinical trial being populated by volunteers?
"Affirmative, the records on clinicaltrials.gov demonstrate that recruitment for this medical trial is ongoing. The study was initially shared to the public on February 1st 2023 and has since been updated as recent as January 11th of the same year. It aims to enroll 50 individuals between 2 locations."
Could you please elucidate the primary aims of this investigation?
"According to the research data from Kura Oncology, Inc., the primary goal of this clinical trial is to assess the safety profile of DLT over a 28-day period. Besides that main outcome measure, secondary objectives such as exploring tipifarnib and osimertinib's pharmacokinetic properties, evaluating circulating tumor DNA alteration prevalence in both ctDNA positive and negative patients and measuring clearance rates for those who were ctDNA positive at baseline are being investigated."
Share this study with friends
Copy Link
Messenger